| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Kinsmen Laboratory of Neurological Research (Drs. Yasojima, E.G. McGeer, and P.L. McGeer), Department of Psychiatry, University of British Columbia, Vancouver, Canada; and the Human Brain and Spinal Fluid Resource Center (Dr. Tourtellotte), Neurology Research, VA West Los Angeles Healthcare Center, Los Angeles, CA.
Address correspondence and reprint requests to Dr. Patrick L. McGeer, Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; e-mail: mcgeerpl{at}interchange.ubc.ca
Objective:— To evaluate the hypothesis that cyclooxygenase-2 (COX-2) is linked to the pathology of ALS by determining whether COX-2 mRNA levels are upregulated in ALS spinal cord.
Methods:— Spinal cord from 11 ALS cases and 27 controls consisting of 15 cases of Alzheimer disease (AD), six cases of Parkinson disease (PD), three cases of cerebrovascular disease, and three control cases were analyzed. Total RNA was extracted and reverse transcriptase-PCR analysis performed for the mRNA of COX-2, COX-1, the microglial marker CD11b, and the housekeeping gene cyclophilin.
Results:— In ALS compared with non-ALS spinal cord, COX-2 mRNA was upregulated 7.09-fold (p < 0.0001), COX-1 1.14-fold (p = 0.05), and CD11b 1.85-fold (p = 0.0012). COX-2 mRNA levels in AD, PD, cerebrovascular disease, and control cases were each significantly lower than in ALS and were not significantly different from each other. Western blots of the protein products were in general accord with the mRNA data, with COX-2 protein levels being upregulated 3.79-fold compared with non-ALS cases (p = 0.015).
Conclusions:— The strong upregulation of COX-2 mRNA in ALS is in accord with studies in the superoxide dismutase transgenic mouse model in which COX-2 upregulation occurs. Taken in conjunction with evidence of a neuroprotective effect of COX-2 inhibitors in certain animal models and in organotypic cultures, the data are supportive of a possible future role for COX-2 inhibitors in the treatment of ALS.
This article has been cited by other articles:
|
|
 |
|
  R. B. Choudry and M. E. Cudkowicz Clinical Trials in Amyotrophic Lateral Sclerosis: The Tenuous Past and the Promising Future J. Clin. Pharmacol., December 1, 2005; 45(12): 1334 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schutz, J. Reimann, L. Dumitrescu-Ozimek, K. Kappes-Horn, G. E. Landreth, B. Schurmann, A. Zimmer, and M. T. Heneka The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice J. Neurosci., August 24, 2005; 25(34): 7805 - 7812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zonta, A. Sebelin, S. Gobbo, T. Fellin, T. Pozzan, and G. Carmignoto Glutamate-mediated cytosolic calcium oscillations regulate a pulsatile prostaglandin release from cultured rat astrocytes J. Physiol., December 1, 2003; 553(2): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Almer, P. Teismann, Z. Stevic, J. Halaschek-Wiener, L. Deecke, V. Kostic, and S. Przedborski Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients Neurology, April 23, 2002; 58(8): 1277 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jubelt and J. R. Berger Does viral disease underlie ALS?: Lessons from the AIDS pandemic Neurology, September 25, 2001; 57(6): 945 - 946. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
